GCEA shows us how to value a medicine not in terms of what you’d pay for the stock but what society should be willing to pay for the product itself. In this article, we perform GCEA for Cidara’s CD388, an anti-flu drug candidate.

A New York Times article gives our economist Richard Xie an excuse to reflect on the nuances of family and community spillover of the benefits of certain medicines, and our industry’s inability or reluctance to try to measure them.